Drug Trial Radar · NCT06033742
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Nov 13, 2021
Primary completion
Mar 24, 2023
Study completion Mar 24, 2023
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this first-in-human study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-10374 in healthy subjects.
Conditions
- Psoriasis
Interventions
HS-10374 tabletsDrug
Single or multiple dosing of HS-10374 orally in a fasting state
HS-10374-matched placebo tabletsDrug
Single or multiple dosing of HS-10374-matched placebo orally in a fasting state
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuationTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)
- Number of participants with clinical laboratory abnormalitiesTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)
- Number of participants with abnormalities of vital signsTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)
- Number of participants with abnormalities of physical examinationTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)
- Number of participants with abnormalities of electrocardiogram (ECG) parametersTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.